Delivery Order SPE2DB22D3019-SPE2DB26FK2ST
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Candesartan Cilexetil 32 mg tablets (90-count) with a ceiling value of $1,509.76. This non-set-aside, firm fixed-price delivery order is scheduled for completion by August 11, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a routine pharmaceutical procurement supporting federal medical supply...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on May 30, 2025, for the supply of Candesartan Cilexetil 16 mg tablets (90-count) with a ceiling value of $102,998.84. This firm fixed-price delivery order, with an ultimate completion date of June 2, 2025, represents a competitive award with no set-aside designation. The contract will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, where the company maintains its headquarters...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of Candesartan Cilexetil 16 mg tablets (90-count bottles) with a ceiling value of $1,175.41. This firm fixed-price delivery order, with an ultimate completion date of August 22, 2025, represents a competitive award with no set-aside designation. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Candesartan Cilexetil 32 mg tablets (90-count units) with a ceiling value of $3,511.93. This firm fixed-price delivery order, with an ultimate completion date of August 6, 2025, represents a competitive award with no set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of Candesartan Cilexetil 4 mg tablets (90-count units) with a ceiling value of $2,812.08. This is a firm fixed-price delivery order with an ultimate completion date of August 25, 2025, and was competitively awarded without set-aside designation. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a delivery order valued at $3,201.64 to AmerisourceBergen Drug Corp for the supply of Candesartan Cilexetil 16 mg tablets (90-count) on October 21, 2025, with completion scheduled for October 22, 2025. The contract utilizes firm fixed pricing with no set-aside designation, indicating competitive award to this qualified pharmaceutical distributor. The place of performance is listed as AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp, valued at $3,532.03, for the supply of Candesartan Cilexetil 32 mg tablets in quantities of 90 units. The award was made on September 25, 2025, with an ultimate completion date of September 26, 2025, under a firm fixed-price delivery order contract type with no set-aside designation. The place of performance is located in Conshohocken, Pennsylvania, which serves as AmerisourceBergen's corporate...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Candesartan Cilexetil 32 mg tablets (90-count units) with a ceiling value of $59,408.56. This firm fixed-price delivery order, with an ultimate completion date of August 6, 2025, represents a non-competitive set-aside contract and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Candesartan Cilexetil 16 mg tablets in a quantity of 90 units, with a ceiling value of $1,425.93. This firm fixed-price delivery order, which is expected to be completed by September 12, 2025, represents a non-competitive, non-set-aside procurement issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX). The...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $1,950.76 for Candesartan Cilexetil 8 mg tablets (90-count) on September 2, 2025, with completion targeted for September 3, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The award represents a continuation of AmerisourceBergen's role as a critical...
- SPE2DB22D3019Indefinite Delivery Contract
- SPE2DB22D3019-SPE2DB26FK2STDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 22, 2025, for the supply of Candesartan Cilexetil 32 mg tablets in a quantity of 90 units, with a ceiling value of $4,775.40. This is a firm fixed price delivery order with an ultimate completion date of October 23, 2025, and represents a non-set-aside competitive award. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters and primary distribution operations. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, valued at $999,999,999.00 and extending through December 2026. This comprehensive prime vendor contract serves as a global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies to military healthcare systems, the Defense Health Agency, and other federal healthcare entities. The company's extensive portfolio of federal medical procurement demonstrates its capability to meet DLA requirements across multiple therapeutic domains, supporting military readiness and veteran healthcare needs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.8k | 10/22/25 |